Skip to content

Earnings yield at other companies

Incyte logo
IncyteINCY
7.6%+7.5pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
5%+2.6pp
UroGen Pharma logo
UroGen PharmaURGN
-15.2%-4.6pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-5.1%-1.7pp
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-14.2%-3.3pp
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-11.8%-4.5pp

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s earnings yield?
Tyra Biosciences, Inc. (TYRA) reported earnings yield of -6.4% in Q1 2026.
How has Tyra Biosciences, Inc.'s earnings yield changed year-over-year?
Tyra Biosciences, Inc.'s earnings yield increased by 67.5% year-over-year, from -19.5% to -6.4%.
What is the long-term trend for Tyra Biosciences, Inc.'s earnings yield?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s earnings yield has grown at a 17.4% compound annual growth rate (CAGR), from -4.5% to -8.5%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.